

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number  
**WO 03/059388 A1**

(51) International Patent Classification<sup>7</sup>: A61K 47/02,  
A61P 9/14

(21) International Application Number: PCT/IS03/00002

(22) International Filing Date: 14 January 2003 (14.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
6233 15 January 2002 (15.01.2002) IS

(71) Applicant (for all designated States except US): DELTA  
HF [IS/IS]; Reykjavikurvegi 78, IS-220 Hafnarfjörður  
(IS).

(72) Inventor; and

(75) Inventor/Applicant (for US only): EYJOLFSSON,  
Reynir [IS/IS]; Eyrahlöti 6, IS-220 Hafnarfjörður (IS).

(74) Agent: A & P ARNASON; Efstaleiti 5, IS-103 Reykjavík  
(IS).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SK, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,  
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— of inventorship (Rule 4.17(iv)) for US only

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: FORMULATIONS OF QUINAPRIL AND RELATED ACE INHIBITORS

(57) Abstract: Stable formulations of ACE-inhibitors compounds such as quinapril can be produced with the use of excipients comprising a basic compound, preferably an alkali-oralkaline earth metal carbonate, and an insoluble alkaline-earth metal carbonate, and an insoluble alkaline-earth metal hydrogen phosphate. Tablets of such formulations have good storage stability, dissolution characteristics, and the formulations are suitable for use in drug combinations.

WO 03/059388 A1

## Formulations of Quinapril and related ACE inhibitors

### FIELD OF THE INVENTION

- 5 The present invention is within the field of pharmaceutical formulations of ACE (Angiotensin Converting Enzyme) inhibitors, specifically formulations of quinapril and structurally related compounds.

### 10 TECHNICAL BACKGROUND AND PRIOR ART

- Many of the compounds useful as ACE (Angiotensin Converting Enzyme) inhibitors such as as quinapril and structurally related compounds, are prone to degradation. Specifically, such compounds can degrade via (i) cyclization via internal nucleophilic  
15 reaction to form substituted diketopiperazines, (ii) hydrolysis of the side-chain ester group, and (iii) oxidation to form products having often unwanted coloration.

Certain stabilizing compositions and formulations of such compounds have been suggested and utilized in the prior art.

20

EP 317878 suggests coating an active compound of this type with a polymeric protective coating, or mixing the compound with a physiologically tolerated buffer which ensures that a pH in the weakly acid to weakly alkaline range is set up in a pharmaceutical formulation in the presence of moisture, or both.

25

The Dictionnaire Vidal (1985) Cahier Complémentaire (p. 10, left col.) describes an enalapril maleate drug named RENITEC which as excipients contains lactose and sodium hydrogen carbonate.

- 30 EP 280999B1 suggests similar compositions using alkali or alkaline earth metal carbonates and saccharides as stabilizers for these compounds. Comparative examples therein (see, e.g. Example D) test a formulation with 5.4 mg quinapril hydrochloride, 88.4 mg magnesium carbonate, 5.2 mg gelatin and 1.0 mg magnesium stearate. The formulation, however, shows substantial degradation as  
35 compared with lactose-stabilized formulations and is therefore not useful as a practical pharmaceutical formulation.

Said ACE inhibitor compounds have varied sensitivity and specific formulations need to be tested and optimized for different compounds. Consequently, alternative solutions providing stable formulations will be appreciated.

5

It has now been surprisingly discovered that useful, stable formulations can be produced with use of excipients comprising a basic compound, preferably an alkali or alkaline-earth metal carbonate, and an insoluble alkaline-earth metal hydrogen phosphate is further used as a preferred filler substance. Surprisingly, a saccharide compound for stabilization is not needed in such formulations.

10

The pH of the formulations of the present invention is dominated by the basic stabilizer.

15

Tablets of such formulations have good storage stability, dissolution characteristics, and the formulations are suitable for use in drug combinations.

In one embodiment, 45% of magnesium carbonate is mixed with 3.9% quinapril hydrochloride with the addition of 33% calcium hydrogen phosphate ( $\text{CaHPO}_4$ ).


20

Additional specific embodiments and experimental stability test results are disclosed in the Detailed description below and enclosed Examples.

#### DETAILED DESCRIPTION


25

The pharmaceutical formulation of the present invention comprises 0.5 – 50 wt%, such as about 1-25 wt%, including about 1-15 wt% of a compound of formula I:



I

wherein R<sup>1</sup> is hydrogen or alkyl having one to five carbon atoms; R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl or the group



in which A and B independently denote hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl and n is 1-4; R<sup>3</sup> and R<sup>4</sup> together with the atoms they are connected to form a heterocyclic,

5 mono-, di-, or tricyclic ring system which is optionally substituted with C<sub>1</sub>-C<sub>4</sub> alkoxy; R<sup>5</sup> is methyl or phenyl; or any pharmaceutically acceptable salt thereof;

5 – 90 wt% of an alkali or alkaline earth metal carbonate, such as in the range of about 10 – 90 wt%, including the range of about 15 – 75 wt% and preferably in the range of about 25 – 75 wt%, such as about 25 – 50 wt% or about 30 – 50 wt%;

10 5 – 90 wt% including the range of about 10 – 90 wt% of an alkali or alkaline earth metal salt of hydrogen phosphate which is preferably an insoluble alkaline-earth metal salt of hydrogen phosphate, such as in the range of about 15 – 75 wt%, such as the range of about 20 – 60 wt%, and preferably in the range of about 25 – 50 wt%, or in the range of 15 – 30 wt%;

15 with the proviso that the formulation does not contain a substantial amount of a saccharide compound.

In this context a substantial amount of a saccharide compound is meant to include any amount that would generally be considered to have a stabilizing effect on the  
20 active compound, such as more than about 10 wt%, and more preferably including an amount which is more than about 5 wt%, or even more preferably including any amount of a saccharide compound which is more than about 2 wt%.

The alkaline earth metal carbonate may suitably be selected from magnesium  
25 carbonate, sodium hydrogen carbonate and sodium carbonate.

In preferred embodiments, the amount of the alkaline earth metal carbonate is at least the equivalent of the amount of the active compound of formula I, such as e.g. at least about twice the equivalent, or at least about three times the equivalent of the  
30 amount of the active compound.

The term equivalent in this context refers to the conventional ionic equivalent term, one equivalent of a substance participating in a neutralization reaction is that amount of a substance that either contributes or consumes 1 mol of hydrogen ions in that  
35 reaction. I.e. for a monoacidic compound such as ramipril and a monobasic alkaline compound such as NaHCO<sub>3</sub>, the equivalent ratio of the compounds is the same as

the molar ratio; for a diacidic compound such as quinapril HCl stabilized with  $\text{NaHCO}_3$ , one equivalent of  $\text{NaHCO}_3$  equals two moles of  $\text{NaHCO}_3$ ; and likewise for a diacidic compound and dibasic alkaline compound such as  $\text{Na}_2\text{CO}_3$ , the equivalent ratio is again the same as the molar ratio. (See, e.g. Skoog, West, Holler

5 *Fundamentals of Analytical Chemistry* 5th Ed., Saunders College Publishing, NY, 1988).

As mentioned, the pH of the formulations are dominated by the basic stabilizing excipient, i.e., the alkali or alkaline-earth metal carbonate.

10

The ACE inhibitor compound is generally selected from enalapril, delapril, lisinopril, moexipril, perindopril, quinapril, ramipril,trandolapril, and pharmaceutically acceptable salts thereof. In particular, stable formulations of quinapril or a salt thereof are suitably manufactured according to the invention disclosed herein.

15

In yet further useful embodiments, the formulation of the present invention further comprises in the range of about 0.5 – 50 wt% of a pharmaceutically active compound selected from the group containing diuretics including hydrochlorothiazide; antitussives including dextromethorphan, dextromethorphan hydrobromide,

20 noscapine, carbetapentane citrate, and chlophedianol hydrochloride; antihistamines including chlorpheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, and phenyltoloxamine citrate; decongestants including phenylephedrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, ephedrine; and alkaloids such as codeine

25 phosphate, codeine sulfate, and morphine. The suitable amount of a further pharmaceutically active compound such as the above listed depends on the particular compound, i.e. the activity of the compound and its suitable dose, and the dose weight of the pharmaceutical formulation.

30

## EXAMPLES

Example 1

- 5 The following materials were combined by the wet granulation method for the manufacture of 5 mg quinapril tablets.

	Quinapril hydrochloride	5.4	mg
	Magnesium carbonate	63	mg
10	Calcium hydrogen phosphate anhydrous	46.4	mg
	Starch pregelatinized	21	mg
	Croscarmellose sodium	2.8	mg
	Magnesium stearate	1.4	mg

15

Example 2

- The following materials were processed by wet granulation for 10/12.5 mg tablets  
20 with Quinapril and Hydrochlorothiazide.

	Quinapril hydrochloride	10.8	mg
	Hydrochlorothiazide	12.5	mg
25	Magnesium carbonate	49	mg
	Calcium hydrogen phosphate anhydrous	42.5	mg
	Starch pregelatinized	21	mg
	Croscarmellose sodium	2.8	mg
30	Magnesium stearate	1.4	mg

Example 3


- 35 Stability of the tablets prepared in the Examples 1-2 were tested at 40°C for 9 days.

Degradation products (%)			
40	<u>Quinapril DKP</u>	<u>Quinaprilat</u>	
	Example 1	0.2	1.2
	Example 2	0.3	0.6
45	(DKP = diketopiperazine)		


## CLAIMS

1. A pharmaceutical formulation comprising:

- 5 a. 0.5 – 50 wt% of a compound of formula I;



wherein R<sup>1</sup> is hydrogen or alkyl having one to five carbon atoms; R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl or the group



in which A and B independently denote hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl and n is 1-4; R<sup>3</sup> and R<sup>4</sup> together with the atoms they are connected to form a heterocyclic, mono-, di-, or tricyclic ring system which is optionally substituted with C<sub>1</sub>-C<sub>4</sub> alkoxy; R<sup>5</sup> is methyl or phenyl; and pharmaceutically acceptable salts thereof;

- 15 b. 5 – 90 wt% of an alkali or alkaline earth metal carbonate;

- c. 5 – 90 wt% of an insoluble alkaline-earth metal salt of hydrogen phosphate;

with the proviso that the formulation does not contain a substantial amount of a saccharide compound.

- 20 2. The formulation of claim 1, wherein the alkali or alkaline-earth metal carbonate is selected from magnesium carbonate, sodium hydrogen carbonate and sodium carbonate.

- 25 3. The formulation of claim 1, wherein the amount of the alkaline earth metal carbonate is at least the equivalent of the amount of the active compound of formula I.

4. The formulation of claim 1, wherein the compound of formula I is selected from the group containing enalapril, delapril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and pharmaceutically acceptable salts thereof.
5. The formulation of claim 1 wherein the formulation comprises in the range of about 1 – 15 wt% of the compound of formula 1.
6. The formulation of claim 1 wherein the formulation comprises in the range of about 25 – 75 wt% of the alkali or alkaline earth metal carbonate.
7. The formulation of claim 6 wherein the formulation comprises in the range of about 30 – 50 wt% of the alkali or alkaline earth metal carbonate.
8. The formulation of claim 1 wherein the formulation comprises in the range of about 15 – 75 wt% of the salt of an insoluble alkaline earth metal hydrogen phosphate.
9. The formulation of claim 1 wherein the formulation comprises in the range of about 25 – 50 wt% of the salt of an insoluble alkaline earth metal hydrogen phosphate.
10. The formulation of any of the preceding claims wherein the compound of formula I is quinapril or a pharmaceutically acceptable salt thereof.
11. The formulation of claim 1 further comprising 0.5 – 50 wt% of a pharmaceutically active compound selected from the group containing diuretics including hydrochlorothiazide; antitussives including dextromethorphan, dextromethorphan hydrobromide, noscapine, carbetapentane citrate, and chlophedianol hydrochloride; antihistamines including chlopheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, and phenyltoloxamine citrate; decongestants including phenylephedrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, ephedrine; and alkaloids such as codeine phosphate, codeine sulfate, and morphine.



## INTERNATIONAL SEARCH REPORT

Internationa lication No  
PCT/IS 03/00002

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K47/02 //A61P9/14

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, EMBASE, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 62560 A (DANIEL JANE ELLEN ;WARNER LAMBERT CO (US); WEISS JAY (US); HARRIS) 9 December 1999 (1999-12-09) page 3, line 20-25 page 7, line 11-26 page 8, line 6 -page 9, line 17; claim 1; examples 4,5	1-11
A	EP 0 280 999 A (WARNER LAMBERT CO) 7 September 1988 (1988-09-07) the whole document	1-11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"8" document member of the same patent family

Date of the actual completion of the international search

28 March 2003

Date of mailing of the international search report

10.04.2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

INGRID EKLUND / ELY

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Internati

plication No

PCT/IS 03/00002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9962560	A	09-12-1999	
		AU 3979399 A	20-12-1999
		BR 9910947 A	06-03-2001
		CA 2330581 A1	09-12-1999
		CN 1304322 T	18-07-2001
		EP 1083931 A1	21-03-2001
		HU 0102260 A2	28-03-2002
		JP 2002516881 T	11-06-2002
		NO 20006148 A	04-12-2000
		NZ 508544 A	25-10-2002
		PL 344586 A1	05-11-2001
		TR 200003600 T2	20-04-2001
		WO 9962560 A1	09-12-1999
		US 2002161020 A1	31-10-2002
		US 6417196 B1	09-07-2002
EP 0280999	A	07-09-1988	
		US 4743450 A	10-05-1988
		AT 84210 T	15-01-1993
		AU 597471 B2	31-05-1990
		AU 1130588 A	25-08-1988
		CA 1300510 A1	12-05-1992
		DE 3877226 D1	18-02-1993
		DE 3877226 T2	29-04-1993
		DK 94088 A	25-08-1988
		EP 0280999 A2	07-09-1988
		HK 59496 A	12-04-1996
		IE 60931 B1	07-09-1994
		JP 2619904 B2	11-06-1997
		JP 63225322 A	20-09-1988
		NZ 223407 A	29-08-1989
		PH 26279 A	10-04-1992
		ZA 8800382 A	27-09-1989